Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-12 22:31 • The Motley Fool Positive Axe Cap view: Selective

Broadcom and Qualcomm represent different semiconductor strategies: Broadcom combines hardware with high-margin software and benefits from AI infrastructure demand, while Qualcomm dominates mobile but faces headwinds from weak Chinese demand and competition from in-house chip development. Despite Qualcomm's lower valuation multiples, Broadcom's superior growth prospects and AI exposure make it the better buy for 2026.

Axe note: Broadcom’s AI edge outshines Qualcomm’s mobile challenges for investors watching USD/ZAR-linked tech exposure.

2026-10-12 22:30 • The Motley Fool Positive Axe Cap view: Selective

TSMC reported Q3 revenue of $46.7 billion, up 41% year-over-year and exceeding both management guidance and analyst expectations. The growth is driven by robust AI chip demand, rapid 2-nanometer production ramp-up with premium pricing, and massive capacity expansions. Trading at 27x earnings with a strong competitive moat, TSMC is positioned for sustained mid-20s revenue growth through 2029.

Axe note: TSMC’s stunning Q3 growth highlights the chip race driving tech, with clear echoes for the rand and select JSE plays.

2026-10-12 22:10 • The Motley Fool Positive Axe Cap view: Selective

The article recommends two Dividend King healthcare stocks for passive income: Abbott Laboratories and Johnson & Johnson. Both companies have demonstrated 50+ years of consecutive dividend increases, strong free cash flow, diversified business portfolios, and solid growth prospects. Abbott offers a 2.5% dividend yield with innovative products like the Libre Duo glucose monitor, while J&J pays a 2% yield and is positioned to reach $100 billion in annual revenue with a strong oncology pipeline.

Axe note: Abbott and Johnson & Johnson deliver consistent dividends, but South African investors should tread carefully.